A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms CARMEN CD 305
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 27 Sep 2018 Planned End Date changed from 31 Dec 2021 to 27 Aug 2021.
- 27 Sep 2018 Planned primary completion date changed from 31 Dec 2021 to 27 Aug 2021.
- 02 Jul 2018 Status changed from not yet recruiting to recruiting.